Clinical Trial Update: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML [Phase 1]

View source ↗

Summary

Phase 1 trial update for voruciclib alone or with venetoclax in various B-cell malignancies and acute myeloid leukemia; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Venclyxto (Venetoclax)
• Voruciclib (voruciclib)

Snippet

Sponsor: MEI Pharma, Inc. | Conditions: Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) | Phase 1 | Status: TERMINATED